GlassScriptPhysician profile
Albert S Hartel
NPI 1841304805
$2,923.99
in general payments reported to CMS, 2019-2025
23 companies · $937 in 2025
The $937 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.30 · 2020: $46.47 · 2021: $289 · 2022: $544 · 2023: $657 · 2024: $404 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,964 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.47 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $824.13 | 2019-2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $344.23 | 2022-2025 | Krystexxa, Tezspire |
| Astrazeneca Pharmaceuticals LP | $290.01 | 2020-2025 | Fasenra, Tezspire, Airsupra |
| Novartis Pharmaceuticals Corporation | $278.15 | 2022-2025 | |
| Horizon Therapeutics Plc | $165.56 | 2023 | Krystexxa |
| Davol INC. | $130.16 | 2025 | Phasix Mesh |
| Csl Behring | $98.25 | 2023 | Hizentra, Haegarda |
| Alk-Abello, INC | $97.98 | 2022-2025 | Alternaria Tenuis, Pre-Pen, Timothy, Standardized |
| Pfizer INC. | $89.95 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.18 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $86.69 | 2019-2022 | |
| Pharming Healthcare, INC. | $83.79 | 2021-2025 | Ruconest |
| Ionis Pharmaceuticals, INC. | $50.62 | 2025 | Dawnzera |
| Kaleo, INC. | $49.34 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.89 | 2021-2024 | Glassia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $42.47 | 2021-2023 | |
| Biocryst US Sales Co., LLC | $39.39 | 2021-2023 | Orladeyo |
| Genentech USA, INC. | $23.20 | 2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $20.77 | 2022 | |
| Jubilant Hollisterstier LLC | $19.25 | 2021 | |
| Grifols USA, LLC | $18.86 | 2021 | |
| Galderma Laboratories, L.P. | $17.06 | 2025 | Nemluvio |
| Ars Pharmaceuticals Operations, INC. | $17.06 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Hartel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.